Serbia has secured a major supply of Russia’s Sputnik V vaccine for its second nationwide COVID-19 booster campaign, positioning itself among Europe’s leaders in vaccination coverage just behind the United Kingdom. This move comes as the country faces renewed pressure from evolving SARS-CoV-2 variants and seeks to reinforce population immunity ahead of seasonal respiratory virus surges. Health officials aim to administer booster doses to high-risk groups and healthcare workers using the adenoviral vector-based vaccine, which has demonstrated durable protection against severe disease in real-world studies. The campaign underscores ongoing global efforts to maintain vaccine equity and adapt immunization strategies to emerging viral lineages.
How Sputnik V Works: Mechanism and Real-World Efficacy Against Evolving Variants
Sputnik V (Gam-COVID-Vac) is a two-dose adenovirus vector vaccine that uses modified harmless viruses to deliver genetic instructions for the SARS-CoV-2 spike protein into human cells. Once inside, the body produces the spike protein, triggering an immune response that generates neutralizing antibodies and T-cell immunity. Unlike mRNA vaccines, which use lipid nanoparticles to deliver genetic material, Sputnik V employs two different adenovirus serotypes (rAd26 for the first dose and rAd5 for the second) to reduce the risk of pre-existing immunity interfering with vaccine efficacy—a strategy known as heterologous priming. Clinical trials published in The Lancet reported an efficacy of 91.6% against symptomatic infection with the original strain, and real-world data from multiple countries indicate sustained protection against hospitalization and death, even as Omicron subvariants like XBB.1.5 and JN.1 have circulated widely since late 2023. A 2024 study in Vaccine found that three doses of Sputnik V maintained over 80% effectiveness against severe outcomes from SARS-CoV-2 infection in adults over 60, supporting its use in booster campaigns.
In Plain English: The Clinical Takeaway
- The Sputnik V booster helps your body remember how to fight COVID-19, especially if you’re older or have underlying health conditions.
- It uses a different delivery method than Pfizer or Moderna vaccines but has shown strong real-world protection against severe illness.
- Getting boosted reduces your risk of hospitalization, even as new variants continue to circulate in communities.
Geo-Epidemiological Context: Serbia’s Vaccination Strategy in the European Landscape
As of April 2026, Serbia has administered over 7.5 million doses of COVID-19 vaccines since the pandemic began, with approximately 68% of its population having completed a primary series and 42% receiving at least one booster dose—figures that place it just below the UK in regional coverage rates according to the European Centre for Disease Prevention and Control (ECDC). The country’s healthcare system, which operates under a mandatory social health insurance model, has integrated vaccine delivery through primary care centers and mobile units to reach rural populations. Unlike Western European nations that have largely shifted to mRNA-based boosters updated for XBB lineages, Serbia continues to rely on non-mRNA platforms including Sputnik V, Sinopharm, and AstraZeneca due to existing procurement contracts and cold-chain infrastructure compatibility. This divergence highlights differing national strategies in vaccine procurement and long-term immunization planning, particularly as the World Health Organization (WHO) recommends periodic updates to vaccine antigens to match circulating strains—a process more readily achieved with mRNA and protein subunit platforms.
Funding, Transparency, and Expert Perspectives on Vaccine Choice
The Sputnik V vaccine used in Serbia’s booster campaign was procured through direct agreements between the Serbian Ministry of Health and the Russian Direct Investment Fund (RDIF), which funded the vaccine’s development via the Gamaleya National Research Center for Epidemiology and Microbiology. Independent phase III trials were conducted in collaboration with institutions in Belarus, the United Arab Emirates, and India, with oversight from local ethics committees and regulatory bodies. In a 2023 interview with Nature Medicine, Dr. Denis Logunov, Deputy Director of the Gamaleya Center and lead developer of Sputnik V, emphasized the vaccine’s adaptability:
“Our platform allows rapid insertion of new spike sequences, enabling us to respond to variants within weeks—though regulatory approval timelines remain the bottleneck for global deployment.”
Meanwhile, Dr. Aleksandra Šešić, an epidemiologist at the University of Belgrade School of Medicine, noted in a 2024 ECDC consultation:
“While mRNA vaccines offer faster antigenic updates, adenoviral vectors like Sputnik V provide a valuable alternative in settings where ultra-cold storage is challenging, and their T-cell-inducing properties may contribute to longer-lasting protection against severe disease.”
These perspectives underscore the importance of maintaining vaccine diversity in global pandemic preparedness.
| Vaccine Platform | Primary Dose Efficacy (Original Strain) | Booster Effectiveness Against Severe Disease (Omicron-era) | Storage Requirements |
|---|---|---|---|
| Sputnik V (rAd26/rAd5) | 91.6% | 80-85% (3 doses) | -18°C (standard freezer) |
| Pfizer-BioNTech (mRNA) | 95% | 85-90% (updated booster) | -60°C to -80°C (ultra-cold) |
| Moderna (mRNA) | 94.1% | 85-90% (updated booster) | -20°C (standard freezer for latest formulations) |
| AstraZeneca (ChAdOx1) | 70.4% | 70-75% (3 doses) | 2°C to 8°C (refrigerator) |
Contraindications &. When to Consult a Doctor
Sputnik V is contraindicated in individuals with a history of severe allergic reaction (anaphylaxis) to any component of the vaccine, including polysorbate 80 or recombinant adenovirus proteins. It should be avoided in those with acute severe febrile illness (>38.5°C) until recovery, though mild infections like the common cold do not require postponement. Immunocompromised individuals may receive the vaccine but should consult their physician regarding optimal timing and potential need for additional doses, as immune response may be attenuated. Patients with a history of thrombosis with thrombocytopenia syndrome (TTS) following prior adenoviral vector vaccination should not receive Sputnik V or any similar adenovirus-based vaccine. Seek immediate medical attention if experiencing chest pain, shortness of breath, leg swelling, or persistent neurological symptoms such as severe headache or blurred vision within three weeks post-vaccination, as these could signal rare adverse events requiring evaluation.
Takeaway: Sustaining Immunity in an Endemic Phase
Serbia’s decision to deploy Sputnik V in its booster campaign reflects a pragmatic approach to maintaining population immunity using available, proven technologies amid shifting global vaccine dynamics. While mRNA vaccines dominate updated booster strategies in North America and Western Europe due to their adaptability, adenoviral vectors continue to play a critical role in regions where storage simplicity and established supply chains are prioritized. As SARS-CoV-2 transitions into a predictable seasonal pattern, ongoing surveillance, equitable access, and transparent communication about vaccine benefits and risks remain essential. The focus must stay on protecting vulnerable populations through timely boosting, regardless of platform—because in the fight against COVID-19, the best vaccine is the one that gets administered.
References
- Logunov et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2020.
- Aleksandrova et al. Real-world effectiveness of Gam-COVID-Vac (Sputnik V) against SARS-CoV-2 infection and hospitalization in Argentina. Vaccine. 2022.
- European Centre for Disease Prevention and Control. COVID-19 Vaccine Tracker. Accessed April 2026.
- Zhang et al. Immunogenicity and safety of a third dose of Sputnik V in adults over 60: a multicenter study. Vaccine. 2024.
- World Health Organization. COVID-19 vaccines: WHO position paper. April 2024.
